Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial
코로나바이러스 감염증(COVID-19) 감염이 확인된 병원에 입원한 환자의 레닌-안지오텐신-알도스테론 시스템 차단 관리(The McGill RAAS-COVID-19): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Study Protocol
[키워드] 1:1
48 hour
48 hours
ACE inhibitor
ACE2
Acute kidney injury
Admission
age
aldosterone
All participants
Amendment
Analysis
Anticoagulants
approach
assigned
baseline
Biomarker
Biomarkers
blinded
Blinding
blockade
blood pressure
BNP
C-reactive protein
C-reactive protein (CRP
calculated
calibrated
cardiovascular disease
change
Clinical improvement
clinical trials
collected
comparator
component
Consent
coronavirus disease
COVID-19
COVID-19 diagnosis
COVID-19 infection
COVID-19 patient
creatinine
creatinine)
CRP
database
death
diagnosis of COVID-19
died
discharge
dissemination
domains
doubling
Effect
EGFR
Ejection fraction
element
eligible
Endpoint
enrolment
Estimated
Ethnicity
evaluate
event
exclusion criteria
feasibility
Follow-up
followed by
General Hospital
greater
groups
Health
Health Organization
heart failure
high blood pressure
highest
hospital
ICU
ICU admission
immunopathology
include
Inclusion
inclusion and exclusion criteria
increase
increase in
Increases
indicate
Infection
inhibitor
inhibitors
initial
initiated
intervention arm
intravenous
invasive ventilation
list
Lower
lowest
lymphocyte
Lymphocyte count
lymphocyte counts
mathematical
mathematical model
McGill University
mean rank
mechanical ventilation
medical history
medication
medications
meet
Montreal
Mortality
number
objective
Older
open
open label
Ordinal Scale
outcome
outcomes
participant
Participants
past medical history
Patient
patient cohort
PCR
performed
Prevent
primary end point
primary endpoint
Protein
protocol
provided
RAAS
RAAS inhibitor
random number generator
randomised
randomised controlled trial
randomization
Randomized
Randomized controlled trial
recruitment
reduced
Registration
Renin
required
Sample
Sample size
SARS- CoV2
secondary
secondary endpoint
sensitivity
sensitivity analysis
serum creatinine
Sex
short term
stability
statistical power calculations
status
stroke
study participant
Study protocol
subsequent
supplementary material
System
table
team
the patient
the primary endpoint
therapy
transfer
transferred
Treatment
Trial
troponin
Version
Victoria
ward
website
were excluded
WHO
withdrawn
World Health Organization
[DOI] 10.1186/s13063-021-05080-4 PMC 바로가기 [Article Type] Study Protocol
[DOI] 10.1186/s13063-021-05080-4 PMC 바로가기 [Article Type] Study Protocol